About Zyla Life Sciences

Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA.

At the moment the company generates 30M USD in revenues.

On its last earning announcement, the company reported a loss of -1.81$ per share.

The book value per share is 5.17$

Zyla Life Sciences website

Create a solid portfolio with ZCOR

Add ZCOR to your portfolio and optimize it!


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
30M 75.50% -46M -152.60% -95M -1.81 - - 9M 5.17 -55M - -55M